Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients

References

• Al-Malky, G., S. Dawson, T. Sirimanna, E. Bagkeris, and R. Suri. 2015. “High-Frequency Audiometry Reveals High Prevalence of Aminoglycoside Ototoxicity in Children with Cystic Fibrosis.” Journal of Cystic Fibrosis 14 (2): 248–254. doi:10.1016/j.jcf.2014.07.009.
   PubMed Web of Science ®Google Scholar
• Al-Malky, G., R. Suri, S. Dawson, T. Sirimanna, and D. Kemp. 2011. “Aminoglycoside Antibiotics Cochleotxicity in Paediatric Cystic Fibrosis(CF) Patients: A Study Using Extended High-Frequency Audiometry and Distortion Product Otoacoustic Emissions.” International Journal of Audiology 50 (2): 112–122. doi:10.3109/14992027.2010.524253.
   PubMed Web of Science ®Google Scholar
• American Speech-Language-Hearing Association (ASHA). 1994. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. 36(suppl 12): 11–19.
   Google Scholar
• Beaubien, A. R., K. Karpinski, and E. Ormsby. 1995. “Toxicodynamics and Toxicokinetics of Amikacin in the guinea Pig Cochlea.” Hearing Research 83 (1–2): 62–79. doi:10.1016/0378-5955(94)00192-S.
   PubMed Web of Science ®Google Scholar
• Carhart, R., and J. Jerger. 1959. “Preferred Method for Clinical Determination of Pure-Tone Thresholds.” Journal of Speech and Hearing Disorders 24 (4): 330–345. doi:10.1044/jshd.2404.330.
   Google Scholar
• Cheng, A. G., P. R. Johnston, J. Luz, A. Uluer, B. Fligor, G. R. Licameli, M. A. Kenna, et al. 2009. “Sensorineural Hearing Loss in Patients with Cystic Fibrosis.” Otolaryngology-Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 141 (1): 86–90. doi:10.1016/j.otohns.2009.03.020.
   PubMed Web of Science ®Google Scholar
• Falzon, D., E. Jaramillo, H. J. Schünemann, M. Arentz, M. Bauer, J. Bayona, L. Blanc, et.al. 2011. “WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update.” The European Respiratory Journal 38 (3): 516–528. doi:10.1183/09031936.00073611.
   PubMed Web of Science ®Google Scholar
• Fausti, S., J. Henry, H. Schaffer, D. Olson, R. Frey, and W. McDonald. 1992. “High-Frequency Audiometric Monitoring for Early Detection of Aminoglycoside Ototoxicity.” The Journal of Infectious Diseases 165 (6): 1026–1032. doi:10.1093/infdis/165.6.1026.
   PubMed Web of Science ®Google Scholar
• Garinis, A. C., C. P. Cross, P. Srikanth, K. Carroll, M. P. Feeney, D. H. Keefe, L. L. Hunter, et al. 2017. “The Cumulative Effects of Intravenous Antibiotic Treatments on Hearing in Patients with Cystic Fibrosis.” Journal of Cystic Fibrosis 16 (3): 401–409. doi:10.1016/j.jcf.2017.01.006.
   PubMed Web of Science ®Google Scholar
• Gilbert, D. N. 2000. “Aminoglycosides.” In Principles and Practice of Infectious Diseases. New York: Churchill Livingstone; p. 307–336.
   Google Scholar
• Griffith, D. E., T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, et al. 2007. “An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases.” American Journal of Respiratory and Critical Care Medicine 175 (4): 367–416. doi:10.1164/rccm.200604-571ST.
   PubMed Web of Science ®Google Scholar
• Konrad-Martin, D., W. J. Helt, K. M. Reavis, J. S. Gordon, L. L. Coleman, G. W. Bratt, S. A. Fausti., et al. 2005. “Guidelines for the Audiologic Management of Individuals Treated with Cochleotoxic Drug Therapy.” ASHA Leader 10 (7): 1–14. doi:10.1044/leader.FTR1.10072005.1.
   Google Scholar
• Martins, L., R. E. S. Guimarães, H. M. G. Becker, M. B. Bedran, M. Medeiros, and P. Camargos. 2011. “Low Prevalence of Middle Ear Disease in Cystic Fibrosis Patients.” Jornal De Pediatria 87 (1): 80. doi:10.1590/S0021-75572011000100014.
   PubMed Web of Science ®Google Scholar
• Mulheran, M., P. Hyman-Taylor, K. H.-V. Tan, S. Lewis, D. Stableforth, A. Knox, A. Smyth, et al. 2006. “Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis Patients.” Antimicrobial Agents and Chemotherapy 50 (7): 2293–2299. doi:10.1128/AAC.00995-05.
   PubMed Web of Science ®Google Scholar
• Pedersen, S., T. Jensen, D. Osterhammel, and P. Osterhammel. 1987. “Cumulative and Acute Toxicity of Repeated High-Dose Tobramycin Treatment in Cystic Fibrosis.” Antimicrobial Agents and Chemotherapy 31 (4): 594–599. doi:10.1128/AAC.31.4.594.
   PubMed Web of Science ®Google Scholar
• Prayle, A., and A. Smyth. 2010. “Aminoglycoside Use in Cystic fibrosis: Therapeutic Strategies and Toxicity.” Current Opinion in Pulmonary Medicine 16 (6): 604–610. doi:10.1097/MCP.0b013e32833eebfd.
   PubMed Web of Science ®Google Scholar
• Scheenstra, R. J., H. G. M. Heijerman, C. L. Zuur, D. J. Touw, and E. Rijntjes. 2010. “No Hearing Loss after Repeated Courses of Tobramycin in Cystic Fibrosis Patients.” Acta Oto-Laryngologica 130 (2): 253–258. doi:10.3109/00016480903015150.
   PubMed Web of Science ®Google Scholar
• Wood, P. J., L. L. Ioannides-Demos, S. C. Li, T. J. Williams, B. Hickey, W. J. Spicer, R. E. Hooper, et al. 1996. “Minimisation of Aminoglycoside Toxicity in Patients with Cystic Fibrosis.” Thorax 51 (4): 369–373.
   PubMed Web of Science ®Google Scholar
• Zettner, E., and M. Gleser. 2018. “Progressive Hearing Loss among Patients with Cystic Fibrosis and Aminoglcyoside Treatment.” Otolaryngology—Head and Neck Surgery, Jun 1:194599818782444. doi: 10.1177/0194599818782444. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar